12/01/2019 00:55:29

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immunomedics Inc. – IMMU

NEW YORK, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Immunomedics Inc. (“Immunomedics” or the “Company”) (NASDAQ:  IMMU).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

 [Click here to join a class action]

The investigation concerns whether Immunomedics and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. 

On December 17, 2018, FDAnews.com published an article entitled “FDA Hits Immunomedics for Data Integrity Breach.”  The article reported, in part, that “[t]he FDA cited Immunomedics for a host of violations—including its handling of a data integrity breach—observed at its Morris Plains, New Jersey, drug substance manufacturing facility between August 6 and 14.”  The article further stated that the data breach included “manipulated bioburden samples, misrepresentation of an integrity test procedure in the batch record, and backdating of batch records, such as dates of analytical results.”  Following publication of this article, Immunomedics’ stock price fell sharply, damaging investors.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:

Robert S. Willoughby

Pomerantz LLP

rswilloughby@pomlaw.com

Related content
29 May - 
Immunomedics to Participate in Upcoming Healthcare Conf..
09 May - 
Immunomedics Reports First Quarter 2019 Results and Pro..
07 May - 
Immunomedics To Participate In Upcoming Healthcare Conf..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Shareholder Alert: Securities Class Action Lawsuit Filed Against Eros International PLC – EROS – Kehoe Law Firm, P.C. Investigating Claims on Behalf of Eros Investors
2
UPDATE – PREMIA and AmoyDx Announce Strategic Partnership to Establish Asia Cancer Clinical Genomic Network
3
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Anheuser-Busch InBev SA/NV and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
4
AOS INVESTOR DEADLINE REMINDER: Hagens Berman Reminds A.O. Smith (AOS) Investors of Lead Plaintiff Deadline, Encourages Investors Who Suffered $50,000+ Losses to Contact the Firm
5
Annual Financial Report and Notice of Annual General Meeting

Related stock quotes

Immunomedics Inc 13.01 1.6% Stock price increasing

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 June 2019 23:47:22
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB6 - 2019-06-26 00:47:22 - 2019-06-25 23:47:22 - 1000 - Website: OKAY